Studies in non-small cell lung cancer have shown distinct biologic behavior and prognosis in KRAS/LKB1-, KRAS/TP53- or KRAS/p16-mutated tumors [28]. This evidence concerns the gene STK11 and non-small cell lung carcinoma.